Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring...
the no-union management policy remains unfulfilled. This discrepancy is evidenced by internal documents leaked in November 2025. "As extensively covered by South Korea's major broadcaster MBC, these documents revealed evidence of Unfair Labor...
member of Y-mAbs Therapeutics, where he was appointed CEO in 2023 and led until its acquisition by SERB Pharmaceuticals in 2025. He brings to the Convergent board decades of radiopharmaceutical experience, having served as President, Medical Group...
The launch of the Innovation Central Laboratory is the latest in a series of innovative developments from ARUP. In April 2025, ARUP launched a blood-based biomarker assay to determine whether cognitive decline symptoms in patients ages 60 years and...
anti-cancer treatments included an androgen receptor pathway inhibitor (ARPI) and androgen deprivation therapy (ADT). In 2025, the disease progressed further, and he was enrolled into the Cohort Expansion Phase of the SECuRE study with a baseline...
3 SMART trial — alongside data from the pivotal Phase 2b/3 CLEVER trial—supported the FDA approval of ENFLONSIA in June 2025 and subsequent global regulatory approvals. Interim data from RSV season 1 of the SMART trial were also presented at IDWeek...
of Libevitug began in 2018. Data from its pivotal registrational study (HH003-204) were presented as a Late-Breaker at the 2025 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). This international, multicenter,...
including bispecific and multi-specific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. As of 2025, WuXi Biologics' integrated platform supports 945 projects, approximately 60% of which involve bi- and multi-specific antibodies,...
YouTube, and Facebook. *Source: US in-home wearable pump trial with 15 moms, 5-day usage + post-trial survey, October 2025. About Lansinoh®: For over 40 years, Lansinoh® has been building a community that understands what moms go through, creating...
new global headquarters in Singapore. The appointment follows a thoughtful and considered process. In early September 2025, Novotech’s former CEO Dr. John Moller informed employees of his intention to step down from the position at the end of last...
vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularization (CNV). In November 2025, European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for...
pharmaceutical group governed by a foundation, announced that Voranigo® (vorasidenib) has been awarded the inaugural 2025 Prix Galien Bridges Award for Best Product for Orphan/Rare Diseases, during a ceremony held in Stockholm. The Prix Galien...
was also approved by the European Commission (EC) and the U.S. Food and Drug Administration (FDA) in February and October 2025, respectively. About Eydenzelt® Eydenzelt® is a vascular endothelial growth factor (VEGF) inhibitor referencing Eylea®...
denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. “We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts....
LEQEMBI is currently approved in 51 countries and regions and is under regulatory review in 9 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance dosing after 18 months of IV treatment every two...
Jazz Pharmaceuticals plc announced that the company will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting taking place November 19-23 in Honolulu, Hawaii. The presentations will feature both clinical and...
Asahi Kasei Corporation has earned top honors in the 2025 BioTech Breakthrough Awards, winning the Biomanufacturing Innovation of the Year for its Planova™ FG1 virus removal filter, developed by its Asahi Kasei Bioprocess business unit. Designed...
its lead asset, HCB101, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 5-9, 2025, in National Harbor, Maryland. Both datasets were accepted for late-breaking poster presentations, highlighting the...
of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2025 American College of Allergy, The new data demonstrate that VTAMA cream provided early and consistent response for children aged...
findings were presented at The Liver Meeting® hosted by the American Association for the Study of Liver Diseases (AASLD) 2025 in Washington, D.C. (November 7–11). Late-breaking, real-world data on Livdelzi, the only PBC treatment that provides...
